Investigator Sponsored Research (ISR) & General Research >50K USD
In order to continue to provide an efficient and transparent review process for the Oncology Research Grants program, we are pleased to announce the following application windows for 2022. Our commitment is to review all proposals and send out decision notifications by the notification deadlines below:
| Submission Window | Notification Deadline* |
| Oct 9, 2021 – Jan 6, 2022 | Feb 24, 2022 |
| Jan 7 – Mar 31, 2022 | May 26, 2022 |
| Apr 1 – May 31, 2022 | Jul 28, 2022 |
| Jun 1 – Aug 31, 2022 | Oct 27, 2022 |
| Sep 1, 2022 – Jan 5, 2023 | Mar 2, 2023 |
* Please note that all studies involving avelumab will not be part of this review schedule due to inter-company Alliance review process.
Important note for applicants: Please do not wait until the submission deadline to enter your request into the online portal. Plan to apply early to allow time for clarification questions and to ensure completeness.
Qualified researchers are invited to submit investigator-sponsored research (ISR) and General Research proposals, according to the guidance and instructions found on the Pfizer ISR portal at www.Pfizer.com/ISR. All proposals must be submitted via the ISR submission portal. An ISR proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for ISR and General Research submissions are made by the applicable Pfizer global review committee. A formal notification regarding the status of your application will be sent on or before the posted notification date.
Pfizer support will only be extended upon the execution of an agreement. For any questions, please send an email to GlobalMedicalGrants@pfizer.com. A list of Oncology assets available for ISR proposals, including Areas of Interest, are available on www.Pfizer.com/ISR.